5 recruiting, 2 completed, 1 active not recruiting. 3 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Lipodystrophy, Partial, Acquired: new trials by email Literature Review of Lipodystrophy, Partial, Acquired trials Research Report on Lipodystrophy, Partial, Acquired
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metabolic Phenotyping in vEDS No intervention, observational - Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 15 | 2026-03-05 | 2026-04-08 | |
| Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 Tirzepatide, Usual care medications - Lipodystrophy, Partial | Phase 2 | Recruiting | University of Michigan | 32 | 2025-09-08 | 2025-09-09 |
| Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Metreleptin - Partial Lipodystrophy | Phase 4 | Recruiting | Amryt Pharma | 12 | 2024-02-08 | 2025-07-03 |
| Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance Pegvisomant - Insulin Receptor Mutation, Partial Lipodystrophy | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2023-01-23 | 2026-08-18 |
| Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL metreleptin, Placebo - Partial Lipodystrophy | Phase 3 | Active not recruiting | Chiesi Farmaceutici S.p.A. | 69 | 2021-12-17 | 2026-06-15 |
| MEASuRE: Metreleptin Effectiveness And Safety Registry Metreleptin - Generalised Lipodystrophy, Partial Lipodystrophy | Recruiting | Chiesi Farmaceutici S.p.A. | 100 | 2016-10-11 | 2026-07-16 | |
| Lipodystrophy Connect Patient Registry Lipodystrophy | Completed | PatientCrossroads | 257 | 2014-01-01 | 2019-04-22 | |
| Trial of Leptin Replacement Therapy in Patients With Lipodystrophy Leptin, Placebo - Hypoleptinemia, Generalized Lipodystrophy | Phase 2 / Phase 3 | Completed | University of Texas Southwestern Medical Center | 25 | 2006-04-01 | 2024-03-27 |
Insulin Resistance (3) · Lipodystrophy (3) · Lipodystrophy, Congenital Generalized (3) · Ehlers-Danlos Syndrome, Type IV (1) · Lipodystrophy, Familial Partial (1)
Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Glucose Metabolism Disorders (3) · Hyperinsulinism (3) · Lipid Metabolism Disorders (3) · Lipid Metabolism, Inborn Errors (3) · Metabolism, Inborn Errors (3) · Skin Diseases, Metabolic (3) · Aneurysm (1) · Aortic Dissection (1) · Cardiovascular Diseases (1)
metreleptin (3) · Leptin (1) · Tirzepatide (1) · pegvisomant (1) · recombinant methionyl human leptin (1)
Chiesi Farmaceutici S.p.A. (2) · Amryt Pharma (1) · Cambridge University Hospitals NHS Foundation Trust (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · PatientCrossroads (1) · University of Michigan (1) · University of Texas Southwestern Medical Center (1)
United States (6) · United Kingdom (3) · France (2) · Germany (2) · Italy (2) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Israel (1) · Netherlands (1) · Poland (1) · Spain (1)
Abhimanyu Garg, MD (1) · Elif Oral, MD (1) · Lori Hartnett (1) · Rebecca J Brown, M.D. (1) · Vanessa Rangel Miller, M.S., M.B.A (1)